Hepatitis B vaccination status of the study participants (n = 360).

† The top five reasons for non-completion included unavailability of vaccines (28%), forgetting the next appointment date (22.1%), and being too busy to go for vaccination (8.8%), cost of vaccine (7.4%) and was told that two doses were enough (7.4%).</p

Multivariable analysis of HBV vaccine uptake and associated factors.

Multivariable analysis of HBV vaccine uptake and associated factors.</p

Socio-demographic and other characteristics of the participants.

Socio-demographic and other characteristics of the participants.</p

Adverse events leading to change or discontinuation of itraconazole therapy for both Group A and B patients.

<p>Adverse events leading to change or discontinuation of itraconazole therapy for both Group A and B patients.</p

Adverse events leading to change or discontinuation of voriconazole therapy for both Group A and B patients.

<p>Adverse events leading to change or discontinuation of voriconazole therapy for both Group A and B patients.</p

Variations in the <i>Aspergillus</i>-specific IgG at baseline, 6 months and 12 months for patients who were only on voriconazole (A) or itraconazole (B) for 12 months and for patients in whom voriconazole (C) or itraconazole (D) was discontinued.

<p><b>Key</b>: <b>+</b>, mean score.: <b>Middle bar</b>, Median.</p

Weight, <i>Aspergillus</i> IgG, quality of life score, and MRC dyspnoea scores for all patients evaluated at baseline, 6 and 12 months.

<p>N = 206.</p

Patients selection, stratification and treatment course for all the patients referred to the National Aspergillosis Centre over 24 months.

<p>Abbreviation: <b>NAC</b>. National Aspergillosis Centre.</p

Change in St. George’s quality of life score at baseline, 6 months and 12 months for patients who were only on voriconazole (A) and itraconazole (B) for 12 months and for patients in whom voriconazole (C) or itraconazole (D) was discontinued.

<p><b>Key</b>: <b>+</b>, mean score: <b>Middle bar</b>, Median.</p

Weight, <i>Aspergillus</i> IgG, quality of life score, and MRC dyspnoea scores for patients not on any therapy at 12 months evaluated at baseline, 6 and 12 months.

<p>N = 56.</p